KALA BIO, Inc. (KALA) shareholders
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David E. Lazar | 49,500,000 | 5.18% | 13D (active) | Jan 30, 2026 |
| Julian C. Baker Joint filing with Baker Bros. Advisors LP (9.99%), Baker Bros. Advisors (GP) LLC (9.99%) and 1 more | 2,890,055 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| LifeSci Capital LLC Joint filing with Andrew McDonald (7.90%), Michael Rice (7.90%) | 2,200,000 | 7.90% | 13G (passive) | Dec 30, 2025 |
| Oxford Finance LLC | 1,620,000 | 16.50% | 13G (passive) | Nov 25, 2025 |
| Labkowski Nachum | 966,991 | 5.00% | 13G (passive) | Oct 14, 2026 |
| Baker Bros. Advisors (GP) LLC Joint filing with Baker Bros. Advisors LP (9.99%), Julian C. Baker (9.99%) and 1 more | 744,759 | 9.99% | 13G (passive) | Oct 2, 2025 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (9.99%), Baker Bros. Advisors (GP) LLC (9.99%) and 1 more | 744,759 | 9.99% | 13D (active) amendment | Sep 30, 2025 |
| Bihua Chen Joint filing with Cormorant Asset Management, LP (9.99%) | 609,027 | 9.99% | 13G (passive) | Dec 31, 2024 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (6.70%), Point72 Capital Advisors, Inc. (6.70%) | 469,229 | 6.70% | 13G (passive) | Sep 4, 2025 |
| Simeon George Joint filing with SR One Capital Fund II Aggregator, LP (5.50%), SR One Capital Partners II, LP (5.50%) and 1 more | 411,000 | 5.50% | 13D (active) amendment | Sep 29, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KALA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 220,623 | 1.14% | $381.68K | +219,412 | 0.00% |
| Geode Capital Management, LLC | 145,152 | 0.75% | $251.11K | +139,931 | 0.00% |
| Vanguard Fiduciary Trust Co | 101,396 | 0.52% | $175.42K | +100,803 | 0.00% |
| BlackRock, Inc. | 71,542 | 0.37% | $123.77K | +71,326 | 0.00% |
| Northern Trust Corp | 41,606 | 0.22% | $71.98K | +41,376 | 0.00% |
| Qube Research & Technologies Ltd | 11,073 | 0.06% | $19.16K | New | 0.00% |
| Goldman Sachs Group Inc | 10,921 | 0.06% | $18.89K | +10,640 | 0.00% |
| UBS Group AG | 9,057 | 0.05% | $15.67K | +7,720 | 0.00% |
| Tower Research Capital LLC (TRC) | 616 | 0.00% | $1.07K | New | 0.00% |
| Barclays PLC | 608 | 0.00% | $1.05K | New | 0.00% |
| Morgan Stanley | 28 | 0.00% | $48 | −31 | 0.00% |
| Caitong International Asset Management Co., Ltd | 10 | 0.00% | $17 | New | 0.00% |
| International Assets Investment Management, LLC | 2 | 0.00% | $4 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 1M | 3.2% | 4 / 7 | 1 / 18 | 1M | 0M |
| Q1 2026 | 27 | 0M | 0.2% | 8 / 8 | 2 / 8 | 0M | 0M |
| Q4 2025 | 29 | 0M | 0.3% | 11 / 3 | 7 / 4 | 0M | 0M |
| Q3 2025 | 22 | 0M | 0.2% | 5 / 9 | 4 / 10 | 0M | 0M |
| Q2 2025 | 28 | 0M | 0.4% | 5 / 7 | 4 / 4 | 0M | 0M |
| Q1 2025 | 27 | 0M | 0.4% | 5 / 8 | 2 / 9 | 0M | 0M |
| Q4 2024 | 32 | 0M | 0.4% | 8 / 7 | 4 / 2 | 0M | 0M |
| Q3 2024 | 26 | 0M | 0.2% | 5 / 4 | 4 / 6 | 0M | 0M |
| Q2 2024 | 28 | 0M | 0.2% | 5 / 8 | 5 / 5 | 0M | 0M |
| Q1 2024 | 28 | 0M | 0.1% | 4 / 4 | 8 / 0 | 0M | 0M |
| Q4 2023 | 24 | 0M | 0.1% | 2 / 7 | 2 / 3 | 0M | 0M |
| Q3 2023 | 25 | 0M | 0.1% | 1 / 5 | 6 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held KALA in Q2 2026, 96% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KALA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 220,623 | 1.14% | $381.68K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 5,633 | 0.03% | $12.56K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 3,822 | 0.02% | $8.52K | 0.00% | May 31, 2026 |
| Total Stock Market Index Trust | 355 | 0.00% | $614 | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 236 | 0.00% | $526 | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 152 | 0.00% | $339 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Avraham Minkowitz | Chief Executive Officer, Director | – | – | Feb 9, 2026 |
| David E. Lazar | Chief Executive Officer, Director | 0 | – | Dec 22, 2025 |
| Romulus K. Brazzell | SEE REMARKS | 35,952 | 0.19% | Oct 24, 2025 |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | 28,906 | 0.15% | Oct 24, 2025 |
| Darius Kharabi | CHIEF BUSINESS OFFICER | 41,760 | 0.22% | Oct 24, 2025 |
| Brendan P. Purdy | Director | – | – | Feb 9, 2026 |
| Yonatan C. Colman | Director | – | – | Feb 9, 2026 |
| Chaim D. Berger | Director | – | – | Feb 9, 2026 |
| Hillel D. Posen | Director | – | – | Feb 9, 2026 |
| Todd Bazemore | Director | 35,933 | 0.19% | Oct 24, 2025 |
| Mark T. Iwicki | Director | 103,540 | 0.54% | Oct 24, 2025 |
| Andrew I. Koven | Director | 16,972 | 0.09% | Jun 17, 2025 |
| Howard B. Rosen | Director | 16,502 | 0.09% | Jun 17, 2025 |
| Gregory D. Perry | Director | 13,344 | 0.07% | Jun 17, 2025 |
| C. Daniel Myers | Director | 10,374 | 0.05% | Jun 17, 2025 |
| Marjan Farid | Director | 10,242 | 0.05% | Jun 17, 2025 |
| Finance Llc Oxford | 10% owner | 1,620,000 | 8.38% | Dec 3, 2025 |
| Bros. Advisors Lp Baker | – | – | – | Oct 2, 2025 |
| Bros. Advisors (GP) LLC Baker | – | – | – | Oct 2, 2025 |
| Felix Baker | – | 118,496 | 0.61% | Oct 2, 2025 |
| Julian Baker | – | 46,480 | 0.24% | Oct 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark T. Iwicki Director | Oct 23, 2025 | Sale | −154,894 | $0.81 | $125.46K | 103,540 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Oct 23, 2025 | Sale | −967 | $0.82 | $793 | 28,906 |
| Romulus K. Brazzell SEE REMARKS | Oct 22, 2025 | Sale | −46,748 | $0.83 | $38.80K | 35,952 |
| Darius Kharabi CHIEF BUSINESS OFFICER | Oct 22, 2025 | Sale | −20,806 | $0.83 | $17.27K | 41,760 |
| Todd Bazemore Director | Oct 22, 2025 | Sale | −47,768 | $0.83 | $39.65K | 35,932 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Oct 22, 2025 | Sale | −32,230 | $0.83 | $26.75K | 29,873 |
| Julian Baker – | Oct 1, 2025 | Sale | −50,640 | $1.38 | $69.88K | 46,480 |
| Julian Baker – | Oct 1, 2025 | Sale | −462,967 | $1.38 | $638.89K | 425,006 |
| Julian Baker – | Sep 30, 2025 | Sale | −195,425 | $1.60 | $312.68K | 887,973 |
| Julian Baker – | Sep 30, 2025 | Sale | −21,376 | $1.60 | $34.20K | 97,120 |
| Todd Bazemore SEE REMARKS | Jun 24, 2025 | Sale(10b5-1 plan) | −4,058 | $4.01 | $16.27K | 83,699 |
| Darius Kharabi CHIEF BUSINESS OFFICER | Jun 24, 2025 | Sale(10b5-1 plan) | −4,511 | $4.01 | $18.09K | 62,566 |
| Romulus K. Brazzell SEE REMARKS | Jun 24, 2025 | Sale(10b5-1 plan) | −5,251 | $4.01 | $21.06K | 82,698 |
| Mark T. Iwicki Director | Jun 24, 2025 | Sale(10b5-1 plan) | −13,227 | $4.01 | $53.04K | 258,433 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Jun 24, 2025 | Sale(10b5-1 plan) | −3,631 | $4.01 | $14.56K | 62,100 |
| Gregory D. Perry Director | Jun 15, 2025 | Award | +2,450 | – | – | 13,344 |
| Howard B. Rosen Director | Jun 15, 2025 | Award | +2,450 | – | – | 16,240 |
| Marjan Farid Director | Jun 15, 2025 | Award | +2,450 | – | – | 10,242 |
| C. Daniel Myers Director | Jun 15, 2025 | Award | +2,450 | – | – | 10,374 |
| Andrew I. Koven Director | Jun 15, 2025 | Award | +3,050 | – | – | 16,972 |
| Mark T. Iwicki Director | Jun 15, 2025 | Award | +2,450 | – | – | 271,660 |
| Mark T. Iwicki Director | Jun 3, 2025 | Sale(10b5-1 plan) | −10,866 | $3.74 | $40.64K | 269,210 |
| Darius Kharabi CHIEF BUSINESS OFFICER | Jun 3, 2025 | Sale(10b5-1 plan) | −730 | $3.74 | $2.73K | 67,077 |
| Romulus K. Brazzell SEE REMARKS | Jun 3, 2025 | Sale(10b5-1 plan) | −3,687 | $3.74 | $13.79K | 87,949 |
| Mark T. Iwicki Director | Jun 3, 2025 | Sale(10b5-1 plan) | +10,866 | $3.74 | $40.64K | 269,210 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Jun 3, 2025 | Sale(10b5-1 plan) | −2,850 | $3.74 | $10.66K | 65,731 |
| Todd Bazemore SEE REMARKS | Jun 3, 2025 | Sale(10b5-1 plan) | −3,390 | $3.74 | $12.68K | 87,757 |
| Romulus K. Brazzell SEE REMARKS | Jan 6, 2025 | Sale(10b5-1 plan) | −2,446 | $7.63 | $18.66K | 92,418 |
| Romulus K. Brazzell SEE REMARKS | Jan 6, 2025 | Award | +10,100 | – | – | 94,864 |
| Mark T. Iwicki CHIEF EXECUTIVE OFFICER, Director | Jan 6, 2025 | Award | +22,100 | – | – | 285,855 |
| Mark T. Iwicki CHIEF EXECUTIVE OFFICER, Director | Jan 6, 2025 | Sale(10b5-1 plan) | −5,779 | $7.63 | $44.09K | 280,076 |
| Todd Bazemore SEE REMARKS | Jan 6, 2025 | Sale(10b5-1 plan) | −1,993 | $7.63 | $15.21K | – |
| Todd Bazemore SEE REMARKS | Jan 6, 2025 | Award | +10,100 | – | – | – |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Jan 6, 2025 | Sale(10b5-1 plan) | −1,706 | $7.63 | $13.02K | 68,581 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Jan 6, 2025 | Award | +10,100 | – | – | 70,287 |
| Darius Kharabi CHIEF BUSINESS OFFICER | Jan 6, 2025 | Award | +10,100 | – | – | 69,828 |
| Darius Kharabi CHIEF BUSINESS OFFICER | Jan 6, 2025 | Sale(10b5-1 plan) | −2,021 | $7.63 | $15.42K | 67,807 |
| Felix Baker 10% owner | Dec 30, 2024 | Buy | +30,620 | $6.44 | $197.19K | 118,496 |
| Felix Baker 10% owner | Dec 30, 2024 | Buy | +279,939 | $6.44 | $1.80M | 1,083,398 |
| Romulus K. Brazzell SEE REMARKS | Jun 26, 2024 | Sale(10b5-1 plan) | −5,489 | $4.75 | $26.07K | 83,982 |
| Darius Kharabi CHIEF BUSINESS OFFICER | Jun 26, 2024 | Sale(10b5-1 plan) | −5,158 | $4.75 | $24.50K | 59,728 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Jun 26, 2024 | Sale(10b5-1 plan) | −4,163 | $4.75 | $19.77K | 60,187 |
| Mark T. Iwicki CHIEF EXECUTIVE OFFICER, Director | Jun 26, 2024 | Sale(10b5-1 plan) | −15,168 | $4.75 | $72.05K | 263,755 |
| Todd Bazemore SEE REMARKS | Jun 26, 2024 | Sale(10b5-1 plan) | −4,653 | $4.75 | $22.10K | 83,040 |
| Mark S. Blumenkranz Director | Jun 11, 2024 | Award | +1,400 | – | – | 13,091 |
| Andrew I. Koven Director | Jun 11, 2024 | Award | +1,750 | – | – | 13,922 |
| Howard B. Rosen Director | Jun 11, 2024 | Award | +1,400 | – | – | 13,887 |
| C. Daniel Myers Director | Jun 11, 2024 | Award | +1,400 | – | – | 7,924 |
| Marjan Farid Director | Jun 11, 2024 | Award | +1,400 | – | – | 7,792 |
| Gregory D. Perry Director | Jun 11, 2024 | Award | +1,400 | – | – | 10,894 |
| Darius Kharabi CHIEF BUSINESS OFFICER | May 31, 2024 | Sale(10b5-1 plan) | −231 | $6.09 | $1.41K | 64,886 |
| Romulus K. Brazzell SEE REMARKS | May 31, 2024 | Sale(10b5-1 plan) | −2,002 | $6.09 | $12.19K | 89,471 |
| Todd Bazemore SEE REMARKS | May 31, 2024 | Sale(10b5-1 plan) | −2,093 | $6.09 | $12.75K | 87,693 |
| Mark T. Iwicki CHIEF EXECUTIVE OFFICER, Director | May 31, 2024 | Sale(10b5-1 plan) | −7,392 | $6.09 | $45.02K | 278,923 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | May 31, 2024 | Sale(10b5-1 plan) | −1,786 | $6.09 | $10.88K | 64,350 |
| Romulus K. Brazzell SEE REMARKS | Jan 4, 2024 | Sale(10b5-1 plan) | −1,617 | $6.74 | $10.90K | 91,473 |
| Romulus K. Brazzell SEE REMARKS | Jan 4, 2024 | Award | +6,500 | – | – | 93,090 |
| Mark T. Iwicki CHIEF EXECUTIVE OFFICER, Director | Jan 4, 2024 | Sale(10b5-1 plan) | −4,539 | $6.73 | $30.55K | 286,315 |
| Mark T. Iwicki CHIEF EXECUTIVE OFFICER, Director | Jan 4, 2024 | Award | +14,300 | – | – | 290,854 |
| Mary Reumuth CHIEF FINANCIAL OFFICER | Jan 4, 2024 | Sale(10b5-1 plan) | −1,227 | $6.74 | $8.27K | 66,136 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kala Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 364,612 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Andrew I. Koven Director | Mar 17, 2026 | 14,466 | $3.82K | Mar 17, 2026 | Restricted Stock |
| Charles D Myers Director | Mar 12, 2026 | 9,112 | $2.86K | Mar 12, 2026 | Restricted Stock |
| Howard B. Rosen Director | Mar 12, 2026 | 13,576 | $3.98K | Mar 12, 2026 | Restricted Stock |
| Mark T. Iwicki Director | Oct 23, 2025 | 154,894 | $125.19K | Oct 23, 2025 | Restricted Stock |
| Mary Reumuth Officer | Oct 23, 2025 | 967 | $793 | Oct 23, 2025 | Exercised Shares |
| R K Brazzell Officer | Oct 22, 2025 | 46,748 | $38.96K | Oct 22, 2025 | Performance Shares |
| Todd Bazemore Officer | Oct 22, 2025 | 47,768 | $39.69K | Oct 22, 2025 | Restricted Stock |
| Darius Kharabi Officer | Oct 22, 2025 | 20,806 | $17.28K | Oct 22, 2025 | Restricted Stock |
| Mary Reumuth Officer | Oct 22, 2025 | 32,230 | $26.73K | Oct 22, 2025 | Restricted Stock |
| Todd Bazemore Officer | Jun 24, 2025 | 4,058 | $16.27K | Jun 24, 2025 | Restricted Stock Unit Vesting |
| Mary Reumuth Officer | Jun 24, 2025 | 3,631 | $14.56K | Jun 24, 2025 | Restricted Stock Unit Vesting |
| Mark T. Iwicki Director | Jun 24, 2025 | 13,227 | $53.04K | Jun 24, 2025 | Restricted Stock Unit Vesting |
| Romulus K. Brazzell Officer | Jun 24, 2025 | 5,251 | $21.06K | Jun 24, 2025 | Restricted Stock Unit Vesting |
| Darius Kharabi Officer | Jun 24, 2025 | 4,511 | $18.09K | Jun 24, 2025 | Restricted Stock Unit Vesting |
| Mark T. Iwicki Director | Jun 3, 2025 | 10,866 | $40.64K | Jun 3, 2025 | Restricted Stock Unit Vesting |
See a number that looks wrong?